Inhibrx (INBX) Expected to Announce Earnings on Thursday

Inhibrx (NASDAQ:INBX) is expected to post its quarterly earnings results before the market opens on Thursday, February 13th. Analysts expect Inhibrx to post earnings of ($2.88) per share for the quarter.

Inhibrx Trading Up 5.0 %

Shares of INBX stock opened at $13.56 on Thursday. The firm’s fifty day moving average price is $14.39 and its two-hundred day moving average price is $14.63. Inhibrx has a 1 year low of $10.80 and a 1 year high of $18.95.

Insiders Place Their Bets

In other Inhibrx news, Director Jon Faiz Kayyem purchased 69,686 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was purchased at an average price of $14.23 per share, with a total value of $991,631.78. Following the completion of the purchase, the director now owns 51,093 shares of the company’s stock, valued at approximately $727,053.39. The trade was a -374.80 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Analyst Ratings Changes

Separately, JMP Securities restated a “market perform” rating on shares of Inhibrx in a research note on Wednesday, January 22nd.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.